Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CENATAC pseudogene 1 (CENATACP1) is a genomic locus classified as a pseudogene, related to the protein-coding gene CENATAC (Centrosomal AT-AC Splicing Factor). Unlike the functional CENATAC gene, CENATACP1 does not encode a functional protein and is considered a defunct genetic copy resulting from gene duplication or retrotransposition events. Pseudogenes typically lack biological activity and do not participate in cellular functions such as signal transduction, cell cycle regulation, or disease pathology. Current knowledge does not implicate CENATACP1 in human diseases, drug interactions, or therapeutic targeting.[1][7][9][11] CENATACP1 is a pseudogene, not a protein-coding gene, receptor, enzyme, or transporter; therefore, it is not considered a therapeutic target[1][7][9][11]. There is no evidence of biological function, clinical relevance, or disease association for this pseudogene itself. Sometimes, pseudogenes have regulatory or non-coding RNA roles, but no such role is described for CENATACP1 in current sources[8][11]. The parent gene, CENATAC, is a component of the minor spliceosome, with roles in chromosome segregation and associated with rare congenital disorders when mutated, but these facts do not extend to the pseudogene[2][4]. CENATAC pseudogene 1 (CENATACP1) is a pseudogene; it is not a therapeutic target, lacks function and disease associations, and is not used as a biomarker. Its parent gene, CENATAC, is functionally relevant, but this does not apply to the pseudogene[1][2][4][7][11].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CENATAC pseudogene 1 (CENATACP1).